ATE411387T1 - Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren - Google Patents

Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Info

Publication number
ATE411387T1
ATE411387T1 AT01933020T AT01933020T ATE411387T1 AT E411387 T1 ATE411387 T1 AT E411387T1 AT 01933020 T AT01933020 T AT 01933020T AT 01933020 T AT01933020 T AT 01933020T AT E411387 T1 ATE411387 T1 AT E411387T1
Authority
AT
Austria
Prior art keywords
rabies virus
human monoclonal
nucleic acid
monoclonal antibodies
related methods
Prior art date
Application number
AT01933020T
Other languages
German (de)
English (en)
Inventor
Douglas Hooper
Bernhard Dietzschold
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE411387T1 publication Critical patent/ATE411387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01933020T 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren ATE411387T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16

Publications (1)

Publication Number Publication Date
ATE411387T1 true ATE411387T1 (de) 2008-10-15

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933020T ATE411387T1 (de) 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Country Status (9)

Country Link
US (1) US6890532B2 (enExample)
EP (1) EP1282703B1 (enExample)
JP (1) JP4819285B2 (enExample)
AT (1) ATE411387T1 (enExample)
CA (1) CA2419148C (enExample)
DE (1) DE60136174D1 (enExample)
IL (1) IL152825A (enExample)
RU (1) RU2272809C2 (enExample)
WO (1) WO2001088132A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
WO2002016437A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
ATE557040T1 (de) * 2001-08-21 2012-05-15 Univ Jefferson Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) * 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
SI1851315T1 (sl) * 2005-02-02 2014-06-30 University Of Massachusetts Humana protitelesa proti steklini in njihova uporaba
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU3432389A (en) 1988-04-07 1989-11-03 Farmitalia Carlo Erba S.R.L. Human monoclonal antibodies against rabies virus
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
DE60136174D1 (de) 2008-11-27
WO2001088132A2 (en) 2001-11-22
CA2419148C (en) 2011-07-12
WO2001088132A3 (en) 2002-07-18
IL152825A0 (en) 2003-06-24
JP2004528803A (ja) 2004-09-24
US6890532B2 (en) 2005-05-10
IL152825A (en) 2009-07-20
EP1282703A2 (en) 2003-02-12
CA2419148A1 (en) 2001-11-22
EP1282703B1 (en) 2008-10-15
US20030165507A1 (en) 2003-09-04
JP4819285B2 (ja) 2011-11-24
RU2272809C2 (ru) 2006-03-27

Similar Documents

Publication Publication Date Title
ATE411387T1 (de) Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
ATE413190T1 (de) Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
NZ619953A (en) Human cytomegalovirus neutralizing antibodies and use thereof
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
NZ590891A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
DE602005025525D1 (de) Vollständige humane monoklonale antikörper gegen il-13
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
ATE288502T1 (de) Gezieltes antikörper-verfahren
CY1113037T1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
WO2003039470A3 (en) Polyvalent immunogen of hiv
EP1530579A4 (en) RECOMBINANT ANTIBODIES AND COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
ATE99958T1 (de) Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE416787T1 (de) Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
DE10124393B8 (de) Hitzebeständiger Stahl, Verfahren zur thermischen Behandlung von hitzebeständigem Stahl, und Komponenten aus hitzebeständigem Stahl
DE602006016416D1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
DE60035221D1 (de) Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties